3.690USD+2.07%Mkt Cap: 6.11M USDP/E: —Last update: 2026-05-22
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotama…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap6.11M USD
Enterprise Value10.12M USD
Revenue (TTM)2.00M USD
Gross Profit-41.07M USD
Net Income (TTM)-59.61M USD
Revenue/Share1.586 USD
Last Price3.690 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees41
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.70
PEG—
EV/EBITDA-0.20
EV/Revenue5.06
P/S2.99
P/B-0.16
EPS (TTM)-41.56
EPS (Forward)-1.34
52W Range
3.2601% of range71.50
52W High71.50 USD
52W Low3.260 USD
Profitability
Gross Margin0.00%
Oper. Margin-2519.95%
EBITDA Margin0.00%
Profit Margin-2980.35%
ROE164.71%
ROA-431.06%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-48.20M USD
CapEx (TTM)—
FCF Margin-901.62%
FCF Yield-294.93%
Net Debt4.13M USD
Net Debt/EBITDA-0.08
Balance Sheet
Debt/Equity-0.17
Current Ratio0.15
Quick Ratio0.10
Book Value/Sh-22.4810 USD
Cash/Share1.184 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateApr 6, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.66M
Float1.38M
Insiders5.63%
Institutions23.12%
Short Interest
Short Ratio2.9d
Short % Float8.89%
Short % Out.8.87%
Shares Short147.27K
Short (prev mo.)47.31K
Technical
SMA 505.650 (-34.7%)
SMA 20022.03 (-83.3%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)35.39K
Avg Vol (10d)34.09K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—